Leveraging AI & Automation to Accelerate mRNA Therapeutic Development: Lessons from ABO2203 & Personalised Cancer Vaccines
2:00 pm - Thursday 18th February 2027
- Exploring how AI-driven approaches and automated workflows can accelerate mRNA candidate discovery, platform optimisation and selection against target product profiles
- Sharing development insights from ABO2203, an mRNAencoded CD19×CD3 T-cell engager, and Abogen’s personalised cancer vaccine programmes to demonstrate how platform technologies translate into therapeutic applications
- Applying automation and AI across personalised mRNA vaccine development to reduce development timelines and lower cost of goods
